United States: The Saga Of The Forbidden Fruit, Part 2: FTC Provides Food For Thought In POM Decision

Last Updated: January 25 2013
Article by Amy R. Mudge and Randal M. Shaheen

In one of the least shocking developments since gambling was discovered at Rick's in Casablanca, the full Federal Trade Commission affirmed the decision made last summer by the Commission's ALJ finding that POM Wonderful made deceptive disease claims in its advertising.  Here is our blog post concerning the ALJ's decision.  The Commission, however, found even more of the ads to be deceptive than the ALJ did and ordered stricter injunctive relief.  Throughout the decision, the Commission provides much for advertisers to consider, especially food advertisers. 

The FTC sued POM in September 2010 alleging that POM's ads made deceptive claims that: (i) its products prevented, treated, or reduced the risk of heart disease, prostate cancer, and erectile dysfunction, and (ii) that POM had clinical studies, research and trials to prove those claims. Contentious discovery and an evidentiary hearing that spanned over five months ensued.  The FTC's ALJ found that some of the ads made the challenged claims, but did not provide the FTC staff with all of the relief that it wanted.  The ALJ also held that randomized, placebo-controlled trials ("RCTs") were not required to substantiate the claims made by POM, but that the substantiation offered by POM was inadequate.  Both sides appealed.  In its decision on the appeal, the full Commission, affirmed and expanded the ALJ's finding of liability and expanded the scope of the injunctive relief. 

The Commission examined each of the 43 challenged ads and discussed its findings regarding ad interpretation in a detailed appendix to the opinion.  Based on its analysis of the ads, the Commission found that not only were the 19 ads found by the ALJ found to be false or deceptive indeed false or deceptive but 17 other ads also were false or deceptive.  In so doing, the Commission found that these ads made one or more of the specific disease claims alleged, and not, as POM argued, simply claims about the general health benefits of consuming POM products.  The Commission also rejected POM's argument that the use of qualifiers such as "may" or "can" modified the statements in the ad such that disease claims were not made.  Similarly, the Commission rejected POM's argument that the humor, hyperbole, and parody found in many of the POM ads somehow blocked or modified the disease claims. 

The Commission disagreed with the ALJ's finding that RCTs were not required to substantiate these claims.  Premised on its finding that serious disease claims had been made, the Commission found that the greater weight of the expert evidence offered at trial showed that RCTs were required.  The Commission declined to state how many of such tests would be required, but noted that because POM had failed to produce any RCTs the claims were not substantiated.  The Commission rejected the ALJ's finding that because the products were safe foods not being offered as a substitute for medical treatments a lower level of substantiation was required. 

The Commission dismissed POM's arguments that requiring prior substantiation for claims violated both the First and Fifth Amendments.  However, the Commission did decline to find liability premised on media appearances that two of the individual defendants had made, finding that complaint counsel had failed to show that the appearances constituted commercial speech under the First Amendment (expect more on this issue later). 

Regarding relief, complaint counsel's own experts had stated that one RCT would constitute competent and reliable scientific evidence for the prostate cancer and ED claims.  The Commission, however, ordered as "fencing in" that POM have two RCTS for any future disease claims.  This was consistent with the position the Commission has taken in other recent cases regarding the substantiation required for disease claims.  However, this the first time we have seen the Commission go on record stating that it can require substantiation in an order above what might otherwise be required to adequately substantiate a claim as "fencing in."  In a footnote to her opinion, Commission Ohlhausen objected to this conclusion, noting that it could unduly limit consumer access to useful information and chill First Amendment protected speech.  The outcome here raises the possibility that a company under a consent order might not be able to make a claim, otherwise supported by adequate and competent reliable scientific evidence, because it has been "fenced in" while its rivals, who are not under a similar consent order, might be free to do so.   Expect to hear more about this issue if, as expected, POM appeals.  The Commission, however, rejected staff request that the order require POM to obtain FDA pre-approval for any disease claims, finding the relief not necessary in this matter.  The FTC has, however, entered into orders in other cases that do require FDA pre-approval for certain claims and specifically reserved the right to continue to do so.  The Commission's opinion in POM has led to the somewhat inexplicable position of having consent orders that require FDA preapproval for claims that a product reduces the likelihood of getting a cold or flu but not for POM's claims that its product can treat, prevent or relieve the risk of heart disease, prostate cancer or erectile dysfunction. 

In a rather odd procedural twist, Commissioner Ohlhausen, who authored the Commission's opinion, also wrote a concurrence.  In the concurrence, Commissioner Ohlhausen departed from the majority in finding some of the ads in question to make the challenged claims, explaining that extrinsic evidence would be necessary to find that those ads made the disease claims in question.  As noted above, she also departed from the majority's requirement that two RCTs should be required in the order.  She expressed concern that the majority was being overly aggressive in finding disease claims to be made and that by so doing the Commission might by infringing upon both the First Amendment and the dividing line drawn by the FDA between structure function claims and disease claims.  If POM appeals as expected, those criticisms will likely be echoed. 

This saga seems far from over.  For now, however, food advertisers must continue to be extremely careful in what they say about the health benefits of their products.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions